Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Gains from Investment Securities (2020 - 2024)

Immuneering (IMRX) has 5 years of Gains from Investment Securities data on record, last reported at -$5469.0 in Q4 2024.

  • For Q4 2024, Gains from Investment Securities fell 122.68% year-over-year to -$5469.0; the TTM value through Dec 2024 reached -$6784.0, down 72.23%, while the annual FY2024 figure was -$6784.0, 72.23% down from the prior year.
  • Gains from Investment Securities reached -$5469.0 in Q4 2024 per IMRX's latest filing, down from -$1315.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $3.6 million in Q3 2022 and bottomed at -$5469.0 in Q4 2024.
  • Average Gains from Investment Securities over 5 years is $919013.1, with a median of $156570.0 recorded in 2020.
  • Peak YoY movement for Gains from Investment Securities: soared 833.83% in 2021, then tumbled 122.68% in 2024.
  • A 5-year view of Gains from Investment Securities shows it stood at $343169.0 in 2020, then soared by 733.28% to $2.9 million in 2021, then tumbled by 100.18% to -$5170.0 in 2022, then soared by 52.5% to -$2456.0 in 2023, then plummeted by 122.68% to -$5469.0 in 2024.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were -$5469.0 in Q4 2024, -$1315.0 in Q3 2024, and -$2456.0 in Q4 2023.